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responsibility of XAbstract A simple, rapid and sensitive liquid chromatography-tandem mass spectrometric (LC–MS/
MS) assay method has been developed and fully validated for the simultaneous quantiﬁcation of
atorvastatin, metformin and glimepiride in human plasma. Carbamazepine was used as internal standard
(IS). The analytes were extracted from 200 mL aliquots of human plasma via protein precipitation using
acetonitrile. The reconstituted samples were chromatographed on a Alltima HP C18 column by using a
60:40 (v/v) mixture of acetonitrile and 10 mM ammonium acetate (pH 3.0) as the mobile phase at a ﬂow
rate of 1.1 mL/min. The calibration curves obtained were linear (r2Z0.99) over the concentration range of
0.50–150.03 ng/mL for atorvastatin, 12.14–1207.50 ng/mL for metformin and 4.98–494.29 ng/mL for
glimepiride. The API-4000 LC–MS/MS in multiple reaction monitoring (MRM) mode was used for
detection. The results of the intra- and inter-day precision and accuracy studies were well within the
acceptable limits. All the analytes were found to be stable in a battery of stability studies. The method is
precise and sensitive enough for its intended purpose. A run time of 2.5 min for each sample made it
possible to analyze more than 300 plasma samples per day. The developed assay method was successfully
applied to a pharmacokinetic study in human male volunteers.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
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i’an Jiaotong University.1. Introduction
Type 2 diabetes is a complex metabolic disorder with two
major biochemical defects, namely impaired insulin secre-
tion and impaired insulin action at the periphery. Chronic
hyperglycemia results from these defects. Current Americanlsevier B.V. All rights reserved.
Atorvastatin
Metfomin Glimepiride
Carbamazepine (IS)
Fig. 1 Chemical structures of atorvastatin, metformin, glimepir-
ide and carbamazepine (IS).
S.R. Polagani et al.10Diabetes Association guidelines suggest that all adults with
diabetes should be managed to achieve a low density lipopro-
tein (LDL) cholesterol less than 100 mg/dl employing statins
as ﬁrst-line therapy [1].
Atorvastatin is a lipid-lowering agent that speciﬁcally,
competitively, and reversibly inhibits 3-hydroxy-3-methylglu-
taryl-CoA (HMG-CoA) reductase, which catalyzes the con-
version of HMG-CoA to mevalonic acid, the rate-limiting step
in the cholesterol biosynthesis [2,3]. US FDA (2006) has
approved atorvastatin for use to reduce the risk of stroke
and heart attack in people with type 2 diabetes without
evidence of heart disease. Metformin is an orally administered
biguanide that lowers glucose by reducing hepatic glucose
production and gluconeogenesis and by enhancing peripheral
insulin sensitivity [4–6]. Glimepiride is an oral sulfonylurea
hypoglycemic agent indicated for the treatment of type 2
diabetes mellitus. The primary mechanism of action of
glimepiride for lowering blood glucose appears to be depen-
dent on stimulating the release of insulin from functioning
pancreatic cells [7,8].
Hence, the combination of atorvastatin, metformin
and glimepiride extends release complement each other and
provides reduction in plasma cholesterol along with glycemic
control, thereby providing a comprehensive control of diabetes
and associated dyslipidemia. TRIPILL (Cipla Limited, Mum-
bai, India) is a ﬁxed dose combination of metformin hydro-
chloride (500 mg), atorvastatin (10 mg) and glimepiride (2 mg).
For many patients with type 2 diabetes, monotherapy with an
oral antidiabetic agent is not sufﬁcient to reach target blood
glucose levels and multiple drugs may be necessary to
achieve adequate control [9,10]. In such cases metformin has
been coadministered with glimepiride [4,9]. The combination
of atorvastatin and metformin has greater beneﬁt in
improving liver injury in type 2 diabetes with hyperlipidemia
[11].
As per the literature, several LC–MS/MS methods have
been reported for the determination of atorvastatin [12–22],
metformin [23–33] and glimepiride [34–38] individually or with
some other drugs in biological samples. To date, no LC–MS/
MS method has been reported for the simultaneous determi-
nation of atorvastatin, metformin and glimepiride in human
plasma. Simultaneous determination of atorvastatin, metfor-
min and glimepiride remains difﬁcult using single mode of
separation and extraction due to their different physico-
chemical properties and polarities. To address the pharmaco-
kinetics of the new combined formulation, a sensitive and
speciﬁc method that allows simultaneous measurement of
atorvastatin, metformin and glimepiride in human plasma is
needed. We felt that this simultaneous estimation method will
help the researchers as the three drugs used in this method
were available in market with ﬁxed dose combination.
The present work describes a simple, selective and sensitive
method, which employs simple protein precipitation technique
for sample preparation and liquid chromatography with
electrospray ionization-tandem mass spectrometry for simul-
taneous quantitation of atorvastatin, metformin and glimepir-
ide in human plasma. The application of this assay method to
a clinical pharmacokinetic study in healthy male volunteers
following oral administration of atorvastatin, metformin and
glimepiride is described. The authenticity in the measure-
ment of study data is demonstrated through incurred samples
reanalysis.2. Experimental
2.1. Chemicals and materials
The reference samples of atorvastatin calcium (97.90%),
metformin hydrochloride (99.60%), glimepiride (99.40%)
and IS (98.71%) were procured form Neucon Pharma Pvt.
Ltd., (Goa, India). Chemical structures of these compounds
are presented in Fig. 1. Water used for the LC–MS/MS
analysis was prepared from Milli-Q water puriﬁcation system
procured from Millipore (Bangalore, India). Acetonitrile and
methanol were of HPLC grade and purchased from J.T. Baker
(Phillipsburg, NJ, USA). Analytical grade ammonium acetate
and acetic acid were purchased from Merck Ltd., (Mumbai,
India). The control human plasma sample was procured from
Deccan’s Pathological Labs (Hyderabad, India).
2.2. Instrumentation and chromatographic conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Alltima HP C18 HL column (50 mm 4.6 mm, 3 mm; Grace
Davison, Deerﬁeld, Ireland), a binary LC-20 AD prominence
pump, an auto sampler (SIL-HTc) and a solvent degasser
(DGU-20 A3) were used for the study. Aliquots of the processed
samples (25 mL) were injected into the column, which was kept
at room temperature. The isocratic mobile phase, 60:40 (v/v)
mixture of acetonitrile and 10 mM ammonium acetate (pH
3.0070.05), was delivered at 1.1 mL/min into the electrospray
ionization chamber of the mass spectrometer. Quantitation was
achieved with MS-MS detection in positive ion mode for all the
analytes and the internal standard using an MDS Sciex API-
4000 mass spectrometer (Foster City, CA, USA) equipped with
a Turboionspray TM interface at 550 1C. The ion spray voltage
was set at 4800 V. The source parameters viz. the nebulizer gas,
Simultaneous LC-MS/MS quantiﬁcation of atorvastatin, metformin and glimepiride in human plasma 11curtain gas, auxiliary gas and collision gas were set at 33, 15, 35
and 7 psi, respectively. The compound parameters viz. the
declustering potential (DP), collision energy (CE), entrance
potential (EP) and collision cell exit potential (CXP) were 60,
20, 10, 7 V for atorvastatin, 45, 25, 10, 6 V for metformin, 40, 28,
10, 6 V for glimepiride and 75, 30, 10, 6 V for IS. Detection of
the ions was carried out in the multiple reaction monitoring
(MRM) mode by monitoring the transition pairs of m/z 559.5
precursor ion to the m/z 440.4 for atorvastatin, m/z 130.1
precursor ion to the m/z 60.1 for metformin, m/z 491.5
precursor ion to the m/z 352.6 for glimepiride and m/z 237.2
precursor ion to the m/z 194.1 product ion for the IS.
Quadrupoles Q1 and Q3 were set on unit resolution. The
analysis data obtained were processed by Analyst softwareTM
(version 1.4.2).2.3. Preparation of stock solutions of analytes and IS
Primary stock solutions of atorvastatin, metformin and glime-
piride for preparation of standard and quality control (QC)
samples were prepared from separate weighing. Primary stock
solutions of atorvastatin, metformin, glimepiride and IS at
1000 mg/mL were prepared in acetonitrile and these stocks were
stored at 2–8 1C; they were found to be stable for 15 days. The
stock solutions were suitably diluted with a mixture of acetoni-
trile and water (60:40, v/v; diluent) to prepare working standard
solutions for the purpose of plotting the calibration curve (CC).
Another set of working solutions of atorvastatin, metformin and
glimepiride were made in diluent (from primary stock) at
appropriate dilutions for preparation of QC samples. A working
IS solution (5 mg/mL) was also prepared in diluent. Working
solutions of glimepiride and metformin were prepared in
combination, whereas atorvastatin was prepared separately.2.4. Preparation of calibration curve standards and quality
control samples
Calibration samples were prepared by spiking 950 mL of control
human plasma with the appropriate working standard solution of
the each analyte (25 mL combined dilution of metformin, glime-
piride and 25 mL of atorvastatin). Calibration curve (CC) stan-
dards of atorvastatin, metformin and glimepiride in blank plasma
were prepared by spiking with an appropriate volume of the
working solutions, giving ﬁnal concentrations of 0.50, 1.00, 2.50,
10.05, 20.10, 40.21, 80.41, 120.02, and 150.03 ng/mL for atorvas-
tatin, 12.14, 24.27, 60.08, 121.35, 242.71, 485.42, 724.50, 966.00,
and 1207.50 ng/mL for metformin and 4.97, 9.94, 24.84, 49.68,
99.35, 198.71, 296.58, 395.44, and 494.29 ng/mL for glimepiride.
The CC samples were analyzed along with the quality control
(QC) samples for each batch of plasma samples. The QC samples
were prepared at ﬁve different concentration levels of 0.50 (lower
limit of quantiﬁcation, LLOQ), 1.50 (low quality control, LQC),
25.05 (middle quality control, MQC-1), 90.09 (MQC-2) and
125.13 ng/mL (high quality control, HQC) for atorvastatin,
12.25 (LLOQ), 36.14 (LQC), 182.55 (MQC-1), 676.10 (MQC-2)
and 1081.76 ng/mL (HQC) for metformin and 4.97 (LLOQ),
14.66 (LQC), 74.05 (MQC-1), 274.24 (MQC92) and 438.79 ng/mL
(HQC) for glimepiride in blank plasma. All the prepared plasma
samples were stored at70 1C.2.5. Sample preparation
All frozen subject samples, calibration standards and quality
control samples were thawed and allowed to equilibrate at
room temperature prior to analysis. The samples were vor-
texed to mix for 10 s prior to spiking. 200 mL aliquot of human
plasma sample was mixed with 20 mL of the internal standard
working solution (5 mg/mL of carbamazepine). To this, 50 mL
of the ammonia solution (25%) and 1.0 mL of acetonitrile
were added. After vortex-mixing for 30 s and centrifugating at
4000 rpm for 10 min, the supernatant was transferred to
another clean test tube and evaporated to dryness at 45 1C
under a gentle stream of nitrogen. The residue was reconsti-
tuted with 500 mL of the mobile phase and 25 mL was injected
into LC–MS/MS system.2.6. Method validation
The validation of the above method was carried out as per US
FDA guidelines [40]. The parameters determined were selec-
tivity, sensitivity, matrix effect, linearity, precision, accuracy,
recovery, stability and dilution integrity. Selectivity was
assessed by comparing the chromatograms of six different
batches of blank plasma obtained from six different sources
including one lipemic and one hemolyzed plasma. Potential
interference from commonly used medications acetaminophen,
diphenhydramine, pantoprazole, nicotine, ibuprofen, caffeine
and pseudoephedrine was evaluated. Sensitivity was deter-
mined by analyzing six replicates of plasma samples spiked
with the lowest level of the calibration curve concentrations.
Matrix effect was checked with six different lots of K2-EDTA
plasma. Three replicate samples each of LQC and HQC
were prepared from different lots of plasma (36 QC samples
in total). For checking the linearity standard calibration
curves containing at least nine points (non-zero standards)
was plotted (0.50–150.03 ng/mL for atorvastatin, 12.14–
1207.50 ng/mL for metformin and 4.98–498.29 ng/mL for
glimepiride). In addition, blank plasma samples were also
analyzed to conﬁrm the absence of direct interferences. Intra-
day precision and accuracy were determined by analyzing six
replicates at ﬁve different QC levels on two different days.
Inter-day precision and accuracy were determined by analyz-
ing six replicates at ﬁve different QC levels of ﬁve different
runs. Recoveries of atorvastatin, metformin, glimepiride and IS
were determined by comparing the peak area of extracted
analyte standard with the peak area of non-extracted
standard. Recoveries of atorvastatin, metformin and gli-
mepiride were determined at concentrations of 1.50, 36.14,
14.66 (LQC), 90.09, 676.10, 274.24 (MQC-2) and 125.13,
1081.76, 438.79 ng/mL (HQC), respectively, whereas for
internal standards were determined at a concentration of
5 mg/mL. Dilution integrity was performed to extend the
upper concentration limit with acceptable precision and
accuracy. Six replicates each at a concentration of about
1.6 times of the uppermost calibration standard were
diluted 2- and 4-fold with blank plasma. The diluted
samples were processed and analyzed.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. The stock solution stability at room
temperature and refrigerated conditions (2–8 1C) was
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(stability samples) with the response of the sample prepared
from fresh stock solution. Bench top stability (12 h), processed
samples stability (autosampler stability for 51 h, wet extract
stability for 27 h and reinjection stability for 44 h), freeze-thaw
stability (5 cycles), long-term stability (68 days) were per-
formed at LQC and HQC levels using six replicates at each
level. Samples were considered to be stable if assay values were
within the acceptable limits of accuracy (85–115%) and
precision (r15% RSD).2.7. Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male
subjects (n¼6). The ethics committee approved the pro-
tocol and the volunteers were provided with informed
written consent. Blood samples were collected following
oral administration of atorvastatin (40 mg), metformin
(500 mg) and glimepiride (2 mg) at pre-dose and 0.25, 0.5,
0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 and 48 h, in
K2-EDTA vacutainer collection tubes (BD, Franklin, NJ,
USA). The tubes were centrifuged at 3200 rpm for 10 min
and the plasma was collected. The collected plasma samples
were stored at 70 1C till their use. Plasma samples were
spiked with the IS and processed as per the extraction
procedure described earlier. Along with the clinical samples,
the QC samples at low, middle 1, middle 2 and high
concentration levels were also assayed in triplicate. Plasma
concentration–time proﬁle of atorvastatin, metformin and
glimepiride was analyzed by non-compartmental method
using WinNonlin Version 5.1. An incurred sample re-
analysis (ISR) was also conducted by selecting the 12
subject samples (two samples from each subject) near Cmax
and the elimination phase. The percent change in the value
should not be more than720% [41].3. Results and discussion
3.1. Mass spectrometry
MS parameters were optimized by infusing the standard
analyte solution of 100 ng/mL into the mass spectrometer
using electrospray as the ionization source and operating in
the MRM mode. The signal intensities obtained in positive
mode were much higher than those in negative ion mode since
the analytes and IS have the ability to accept protons.
Protonated form of each analyte and IS, [MþH]þ ion was
the parent ion in the Q1 spectrum and was used as the
precursor ion to obtain Q3 product ion spectra. The most
sensitive mass transition was monitored from m/z 559.5 to
440.4 for atorvastatin, from m/z 130.1 to 60.1 for metformin,
from m/z 491.5 to 352.6 for glimepiride and from m/z 237.2 to
194.1 for the IS. As earlier publications have discussed the
details of fragmentation patterns of atorvastatin [12], metfor-
min [28], glimepiride [35] and IS [39], we are not presenting the
data pertaining to this. LC-MRM is a very powerful technique
for pharmacokinetic studies since it provides sensitivity andselectivity requirements for analytical methods [42]. Thus, the
MRM technique was chosen for the assay development.3.2. Method development
Atorvastatin, metformin and glimepiride have different physico-
chemical properties; it was difﬁcult to set chromatographic
conditions that produced sharp peak shape and adequate
response. The method development includes mobile phase
selection, ﬂow rate, column type and injection volume. Methanol
and acetonitrile were tried in different ratio with buffers like
ammonium acetate, ammonium formate as well as acid additives
like formic acid and acetic acid in varying strength. It was
observed that acetonitrile and 10 mM ammonium acetate (pH
3.070.05) (60:40, v/v) as the mobile phase was most appropriate
to give best sensitivity, efﬁciency and peak shape. Acidic
buffer helped to improve the peak shape and spectral
response. 40% aqueous part was adequate to retain the
polar compound metformin. The use of a short chromato-
graphy column Alltima HP C18 HL (50 mm 4.6 mm,
3 mm) helped in the separation and elution of all three
compounds in a very short time. The total chromatographic
run time was 2.5 min for each run.
Extraction of all analytes from plasma was difﬁcult as
metformin is highly polar, while atorvastatin and glimepiride
are comparatively less polar compounds. Initially both the
extraction methodologies solid phase extraction (SPE) and
liquid–liquid extraction (LLE) were tried using Oasis HLB
cartridges for SPE and different organic solvents like ethyl
acetate, hexane, dichloromethane, diethyl ether and methyl
tert-butyl ether (MTBE) for LLE. The recovery results
obtained were consistent for atorvastatin with negligible
matrix effect but not for metformin. But as the purpose was
to develop a simple, quick and inexpensive method, protein
precipitation (PP) was tested. Also, atorvastatin, metformin,
and glimepiride had more protein binding nature and were
precipitated easily with the single protein precipitant. Thus, in
the present study PP was carried out using ethanol, methanol
and acetonitrile solvents. The extracts were clear but the
recovery was in the range of 70–90% for all the solvents but
not reproducible. Addition of ammonia solution to the plasma
samples in different volume ratios helped in obtaining con-
sistent and reproducible response. Precipitation with acetoni-
trile containing ammonia solution caused the lowest matrix
effect with better peak shape compared to other organic
solvents. When direct residue of the protein precipitant was
injected, the peak shape of atorvastatin was unacceptable at
lower concentration levels and also matrix effect was high.
Hence supernatant was evaporated and the residue was
reconstituted with the mobile phase. The method gave clear
extracts with minimum matrix effect and quantitative extrac-
tion was possible for all the analytes and IS. The mean
recoveries for atorvastatin, metformin, glimepiride and IS
were good and reproducible. Moreover, the validation results
and subject sample analysis study support this extraction
methodology and hence it was accepted in the present study.
It is necessary to use an internal standard to obtain high
accuracy when HPLC is equipped with MS as the detector.
For LC-MS/MS analysis, use of stable isotope-labeled
drugs as internal standards proves to be helpful when a
signiﬁcant matrix effect is possible [43]. Isotope-labeled
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stages of this work, many compounds were investigated in
order to ﬁnd suitable IS, Finally carbamazepine was
selected, based on the chromatographic elution, ionization
and extraction efﬁciency.3.3. Selectivity and chromatography
The degree of interference by endogenous plasma constituents with
the analytes and IS was assessed by inspection of chromatograms
derived from processed blank plasma sample. As shown in Figs.
2–4, no signiﬁcant direct interference in the blank plasma traces
was observed from endogenous substances in drug-free plasma at
the retention time of the analytes. Similarly, no interference was
observed from commonly used medications such as acetamino-
phen, diphenhydramine, pantoprazole, nicotine, ibuprofen, caf-
feine and pseudoephedrine.Fig. 2 Typical MRM chromatograms of atorvastatin (left panel) and
spiked with IS (B), a LLOQ sample along with IS (C).3.4. Sensitivity
The lowest limit of reliable quantiﬁcation for the analytes was
set at the concentration of the LLOQ. The precision and
accuracy at LLOQ concentration were found to be 1.12% and
101.21%; 3.06% and 102.61%; 7.11% and 96.98% for
atorvastatin, metformin and glimepiride, respectively.3.5. Extraction efﬁciency
A simple protein precipitation with acetonitrile proved to be
robust and provided cleanest samples. The recoveries of the
analytes and the IS were good and reproducible. The mean
overall recoveries (with the precision range) of atorvastatin,
metformin and glimepiride were 96.7270.88% (1.62–4.47%),
72.8872.18% (1.16–2.47%) and 74.1672.26% (0.88–2.72%),
respectively. The recovery of the IS was 67.16% with a
precision range of 0.72–0.90%.IS (right panel) in human blank plasma (A), and human plasma
Fig. 3 Typical MRM chromatograms of metformin (left panel) and IS (right panel) in human blank plasma (A), and human plasma
spiked with IS (B), a LLOQ sample along with IS (C).
S.R. Polagani et al.143.6. Matrix effect
No signiﬁcant matrix effect was observed in all the six batches
of human plasma for the analytes at LQC and HQC
concentrations. The precision and accuracy for atorvastatin,
metformin and glimepiride at LQC concentration were found
to be 0.59% and 100.57%; 2.43% and 96.63%; 1.53% and
96.43%, respectively. Similarly, the precision and accuracy for
atorvastatin, metformin and glimepiride at HQC concentra-
tion were found to be 1.83% and 93.93%; 3.15% and 96.42%;
1.74% and 96.67%, respectively.
3.7. Linearity
Nine-point calibration curve was found to be linear over the
concentration range of 0.50–150.03 ng/mL for atorvastatin,
12.14–1207.50 ng/mL for metformin and 4.97–494.29 ng/mL
for glimepiride. After comparing the two weighting models
(1/x and 1/x2), a regression equation with a weighting factor
of 1/x2 of the drug to the IS concentration was found to
produce the best ﬁt for the concentration–detector response
relationship for both the analytes in human plasma. The meancorrelation coefﬁcient of the weighted calibration curves
generated during the validation wasZ0.99.
3.8. Precision and accuracy
The results for intra-day and inter-day precision and accuracy
in plasma quality control samples are summarized in Table 1.
The intra-day and inter-day precision deviation values were all
within 15% of the relative standard deviation (RSD) at low,
middle 1, middle 2 and high quality control levels, whereas
within 20% at LLOQ QCs level. The intra-day and inter-day
accuracy deviation values were all within 100715% of the
actual values at low, middle 1, middle 2 and high quality
control level, whereas within 100720% at LLOQ QCs level.
The results revealed good precision and accuracy.
3.9. Dilution integrity
The upper concentration limits can be extended to 256.51 ng/mL
for atorvastatin, 2048.95 ng/mL for metformin, and 805.70
ng/mL for glimepiride by 1/2 or 1/4 dilution with screened
human blank plasma. The mean back calculated concentrations
Fig. 4 Typical MRM chromatograms of glimepiride (left panel) and IS (right panel) in human blank plasma (A), and human plasma
spiked with IS (B), a LLOQ sample along with IS (C).
Table 1 Intra-day and inter-day precision and accuracy for atorvastatin, metformin and glimepiride.
QC QC (spiked concentration
ng/mL)
Intra-day (n¼12) Inter-day (n¼30)
Mean concentration
found (ng/mL)
Accuracy(%) CV(%) Mean concentration
found (ng/mL)
Accuracy(%) CV(%)
Atorvastatin
LLOQ 0.50 0.50 99.28 1.22 0.50 99.03 1.48
LQC 1.50 1.38 92.07 7.51 1.37 91.24 4.98
MQC1 25.05 25.17 100.52 3.12 24.11 96.28 4.45
MQC2 90.09 87.66 97.30 4.41 85.57 94.98 3.82
HQC 125.13 111.05 88.75 3.36 122.34 97.77 7.75
Metformin
LLOQ 12.25 12.18 99.42 6.03 11.99 97.89 6.16
LQC 36.14 35.15 97.25 1.70 36.08 99.82 3.37
MQC1 182.55 173.73 95.17 1.66 177.35 97.15 4.58
MQC2 676.10 676.37 100.04 1.79 671.99 99.39 1.73
HQC 1081.76 1091.69 100.92 1.56 1068.40 98.77 2.32
Glimepiride
LLOQ 4.97 4.59 92.36 5.56 4.81 96.81 10.75
LQC 14.66 14.21 96.96 3.98 15.09 102.91 7.27
MQC1 74.05 73.76 99.62 3.51 74.99 101.27 5.76
MQC2 274.24 287.68 104.90 3.02 285.16 103.98 2.16
HQC 438.79 455.70 103.85 3.39 445.99 101.64 2.96
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Table 2 Stability tests for atorvastatin, metformin and glimepiride
Stability test Atorvastatin ride
QC (spiked
concentration
ng/mL)
Mean
(ng/mL)
Accuracy/
Stability (%)
Prec
Autosampler stability
(at 5 1C for 51 h)
1.50 1.33 88.72 5.6
125.13 134.75 107.69 4.3
Wet extract stability
(at 2–8 1C for 27 h)
1.50 1.52 101.41 9.4
125.13 137.69 110.05 12.0
Bench top stability
(12 h in ice water bath)
1.50 1.38 91.61 1.4
125.13 128.02 102.32 6.7
Freeze-thaw stability
(six cycles)
1.50 1.49 99.19 7.5
125.13 139.65 111.61 2.1
Reinjection stability
(44 h)
1.50 1.52 110.89 0.8
125.13 126.55 98.14 1.1
Long-term stability (at
70 1C for 68 days)
1.50 1.50 112.29 3.3
125.13 127.71 101.79 4.9
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Table 3 Pharmacokinetic parameters for atorvastatin
(40 mg), metformin (500 mg) and glimepiride (2 mg) (n¼6,
Mean7SD).
PK parameter Atorvastatin Metformin Glimepiride
tmax (h) 0.7570.61 2.4270.38 5.3370.52
Cmax (ng/mL) 59.8711.5 877.57162.2 62.877.9
AUC0–t
(ng h/mL)
213786 685271312 508752
AUC0–inf
(ng h/mL)
236783 719171465 589775
t1/2 (h) 7.9272.72 4.9570.93 8.5571.87
Kel (h–1) 0.1070.04 0.1470.03 0.0870.02
Simultaneous LC-MS/MS quantiﬁcation of atorvastatin, metformin and glimepiride in human plasma 17concentrations for the analytes at their LQC and HQC levels
(Table 2). Thus, the results were found to be within the
acceptable limits during the entire validation.
3.11. Pharmacokinetic study results
In order to verify the sensitivity and selectivity of this method
in a real-time situation, the present method was used to test
for atorvastatin, metformin and glimepiride concentrations in
human plasma samples collected from healthy male volunteers
(n¼6). The mean plasma concentrations vs time proﬁle of
atorvastatin, metformin and glimepiride are shown in Fig. 5.
The pharmacokinetic parameters estimated are shown in
Table 3. These values were in close proximity when compared
with earlier reported values [16,28,36].
3.12. Incurred sample reanalysis
Since the FDA has introduced the necessity of incurred
sample reanalysis evaluation at the Crystal City III
meeting [44] it is necessary to demonstrate assay reproduci-
bility by using dosed subject samples. Incurred sample reana-
lysis (ISR) was performed using two plasma samples from
each subject and re-assayed in a separate batch run. The
differences in concentrations between the ISR and the initial
values for all the tested samples were less than 20% (Table 4),
indicating good reproducibility of the present method.T
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24. Conclusion
In summary, we have developed and validated a rapid,
speciﬁc, reproducible and high-throughput LC-MS/MS
method to quantify atorvastatin, metformin and glimepir-
ide simultaneously using single IS. So far no published
methods are available for the simultaneous quantiﬁcation
of these three drugs in human plasma. Validated methods
are essential for the determination of atorvastatin, metfor-
min and glimepiride concentrations in human plasma
simultaneously for bioequivalence studies. To the best of
knowledge, this is the ﬁrst time that all three analytes were
estimated simultaneously in any of the biological matrix.
The cost-effectiveness, simplicity of the assay and usage of
protein precipitation extraction and sample turnover rate
of less than 2.5 min per sample, make it an attractive
procedure in high-throughput bioanalysis of atorvastatin,
S.R. Polagani et al.18metformin and glimepiride. From the results of all the
validation parameters, we can conclude that the developed
method can be useful for bioavailability/bioequivalence
studies and routine therapeutic drug monitoring with
desired precision and accuracy.
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